The premarket rise in ADXN's stock price could be attributed to investor optimism ahead of the company's presentation at the Biotech Showcase. However, the low volume indicates that the movement might not be strongly supported by high investor interest, which could limit the sustainability of the price increase. The presentation itself could provide more substantial information that could affect the stock's performance.